Department of Hotel Culinary Arts, Yeonsung University, Anyang 430-749, Korea.
Research Center, BIFIDO Co. Ltd., Hongcheon 250-804, Korea.
Nutrients. 2017 Aug 16;9(8):887. doi: 10.3390/nu9080887.
A total of 57 infants hospitalized with rotavirus disease were included in this study. The children were randomly divided into the study's two treatment groups: three days of the oral administration of (i) a probiotics formula containing both BORI and AD031 ( = 28); or (ii) a placebo (probiotic-free skim milk, = 29) and the standard therapy for diarrhea. There were no differences in age, sex, or blood characteristics between the two groups. When the 57 cases completed the protocol, the duration of the patients' diarrhea was significantly shorter in the probiotics group (4.38 ± 1.29, = 28) than the placebo group (5.61 ± 1.23, = 29), with a -value of 0.001. Symptoms such as duration of fever ( = 0.119), frequency of diarrhea ( = 0.119), and frequency of vomiting ( = 0.331) tended to be ameliorated by the probiotic treatment; however, differences were not statistically significant between the two groups. There were no serious, adverse events and no differences in the frequency of adverse events in both groups.
本研究共纳入 57 例轮状病毒病住院婴儿。将患儿随机分为研究的两组治疗组：口服（i）含 BORI 和 AD031 的益生菌配方 3 天（=28）；或（ii）安慰剂（无益生菌脱脂牛奶，=29）和腹泻的标准治疗。两组间年龄、性别或血液特征无差异。当 57 例完成方案时，益生菌组（4.38±1.29，=28）患儿腹泻持续时间明显短于安慰剂组（5.61±1.23，=29），值为 0.001。益生菌治疗后发热持续时间（=0.119）、腹泻频率（=0.119）和呕吐频率（=0.331）等症状有改善趋势，但两组间差异无统计学意义。两组均无严重不良事件，不良事件发生率无差异。
